The purpose of this study is to determine efficacy of SB injection in Non Small Cell Lung Cancer.

All eligible patients will receive SB injection therapy for 4 cycles (14~21 days for each cycle). SB injection treatment could be continue after completion of therapy cycles until 6th cycle. It depends on the investigator's decision and patient's will. Efficacy will be evaluated every two cycles.

Inclusion Criteria:

• Age of 18-70 years

• Patients with histologically or cytologically confirmed Non-Small Cell Lung Cancer

• Patients who had failed more than 1 cycle of standard therapy with advanced or metasatic stage not available to any of resectable surgery or radiotherapy.

• Patients with measurable lesions

• Eatern Cooperative Oncolgy Group status 0 to 2.

• Life expectancy >/= 5 months

• Patients with adequate organ(heart, kidney, liver)and bone marrow function, as defined by

  1. Absolute neutrophil count >/= 1.5 x 10^9/L, Platelet count >/= 100 x 10^9/L
  2. Total bilirubin \